IDEAS home Printed from https://ideas.repec.org/r/aea/aejpol/v10y2018i1p77-112.html
   My bibliography  Save this item

The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Janet Currie & Hannes Schwandt, 2021. "The Opioid Epidemic Was Not Caused by Economic Distress but by Factors That Could Be More Rapidly Addressed," The ANNALS of the American Academy of Political and Social Science, , vol. 695(1), pages 276-291, May.
  2. Aliprantis, Dionissi & Fee, Kyle & Schweitzer, Mark E., 2023. "Opioids and the labor market," Labour Economics, Elsevier, vol. 85(C).
  3. Ruenzi, Stefan & Maeckle, Kai, 2023. "Friends with Drugs: The Role of Social Networks in the Opioid Epidemic," VfS Annual Conference 2023 (Regensburg): Growth and the "sociale Frage" 277574, Verein für Socialpolitik / German Economic Association.
  4. Cornelius A. Rietveld & Pankaj C. Patel, 0. "Prescription opioids and new business establishments," Small Business Economics, Springer, vol. 0, pages 1-25.
  5. Casey B. Mulligan, 2020. "Prices and Federal Policies in Opioid Markets," Working Papers 2020-10, Becker Friedman Institute for Research In Economics.
  6. Orgul Ozturk & Yuan Hong & Suzanne McDermott & Margaret Turk, 2021. "Prescription Drug Monitoring Programs and Opioid Prescriptions for Disability Conditions," Applied Health Economics and Health Policy, Springer, vol. 19(3), pages 415-428, May.
  7. Lowenstein, Christopher, 2024. "“Deaths of despair” over the business cycle: New estimates from a shift-share instrumental variables approach," Economics & Human Biology, Elsevier, vol. 53(C).
  8. Deiana, Claudio & Giua, Ludovica, 2018. "The US Opidemic: Prescription Opioids, Labour Market Conditions and Crime," MPRA Paper 85712, University Library of Munich, Germany.
  9. Aljoscha Janssen & Xuan Zhang, 2023. "Retail Pharmacies and Drug Diversion during the Opioid Epidemic," American Economic Review, American Economic Association, vol. 113(1), pages 1-33, January.
  10. Alexander Ahammer & Martin Halla, 2020. "The Intergenerational Transmission of Opioid Dependence: Evidence from Administrative Data," Economics working papers 2020-10, Department of Economics, Johannes Kepler University Linz, Austria.
  11. Alberto Ortega, 2023. "Medicaid Expansion and mental health treatment: Evidence from the Affordable Care Act," Health Economics, John Wiley & Sons, Ltd., vol. 32(4), pages 755-806, April.
  12. Ericson, Keith Marzilli & Sacarny, Adam & Zhou, Annetta, 2023. "Dangerous prescribing and healthcare fragmentation: Evidence from opioids," Journal of Public Economics, Elsevier, vol. 225(C).
  13. Molly Schnell & Janet Currie, 2018. "Addressing the Opioid Epidemic: Is There a Role for Physician Education?," American Journal of Health Economics, University of Chicago Press, vol. 4(3), pages 383-410, Summer.
  14. Packham, Analisa, 2022. "Syringe exchange programs and harm reduction: New evidence in the wake of the opioid epidemic," Journal of Public Economics, Elsevier, vol. 215(C).
  15. Cotti, Chad D. & Gordanier, John M. & Ozturk, Orgul D., 2020. "The relationship of opioid prescriptions and the educational performance of children," Social Science & Medicine, Elsevier, vol. 265(C).
  16. Deiana, Claudio & Giua, Ludovica & Nistico, Roberto, 2019. "The Economics behind the Epidemic: Afghan Opium Price and Prescription Opioids in the US," IZA Discussion Papers 12872, Institute of Labor Economics (IZA).
  17. David Cho & Daniel I. García & Joshua Montes & Alison E. Weingarden, 2021. "Labor Market Effects of the Oxycodone-Heroin Epidemic," Finance and Economics Discussion Series 2021-025, Board of Governors of the Federal Reserve System (U.S.).
  18. Natali, Ilaria, 2024. "Economic Opportunity and Opioid Regulation: the Case of Codeine in France," TSE Working Papers 24-1563, Toulouse School of Economics (TSE).
  19. Powell, David & Pacula, Rosalie Liccardo & Taylor, Erin, 2020. "How increasing medical access to opioids contributes to the opioid epidemic: Evidence from Medicare Part D," Journal of Health Economics, Elsevier, vol. 71(C).
  20. Amy Finkelstein & Matthew Gentzkow & Dean Li & Heidi L. Williams, 2022. "What Drives Risky Prescription Opioid Use? Evidence from Migration," NBER Working Papers 30471, National Bureau of Economic Research, Inc.
  21. Simone Balestra & Helge Liebert & Nicole Maestas & Tisamarie B. Sherry, 2021. "Behavioral Responses to Supply-Side Drug Policy During the Opioid Epidemic," NBER Working Papers 29596, National Bureau of Economic Research, Inc.
  22. Dhaval Dave & Monica Deza & Brady Horn, 2021. "Prescription drug monitoring programs, opioid abuse, and crime," Southern Economic Journal, John Wiley & Sons, vol. 87(3), pages 808-848, January.
  23. Deiana Claudio & Giua Ludovica, 2021. "The Intended and Unintended Effects of Opioid Policies on Prescription Opioids and Crime," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 21(2), pages 751-792, April.
  24. Shishir Shakya & Jane E. Ruseski, 2023. "The effect of Prescription Drug Monitoring Programs on county‐level opioid prescribing practices and spillovers," Contemporary Economic Policy, Western Economic Association International, vol. 41(3), pages 435-454, July.
  25. Buckles, Kasey & Evans, William N. & Lieber, Ethan M.J., 2023. "The drug crisis and the living arrangements of children," Journal of Health Economics, Elsevier, vol. 87(C).
  26. William N. Evans & Ethan M. J. Lieber & Patrick Power, 2019. "How the Reformulation of OxyContin Ignited the Heroin Epidemic," The Review of Economics and Statistics, MIT Press, vol. 101(1), pages 1-15, March.
  27. Gihleb, Rania & Giuntella, Osea & Zhang, Ning, 2020. "Prescription drug monitoring programs and neonatal outcomes," Regional Science and Urban Economics, Elsevier, vol. 81(C).
  28. Eichmeyer, Sarah & Zhang, Jonathan, 2023. "Primary care providers’ influence on opioid use and its adverse consequences," Journal of Public Economics, Elsevier, vol. 217(C).
  29. Hollingsworth, Alex & Ruhm, Christopher J. & Simon, Kosali, 2017. "Macroeconomic conditions and opioid abuse," Journal of Health Economics, Elsevier, vol. 56(C), pages 222-233.
  30. Thuy D. Nguyen & W. David Bradford & Kosali I. Simon, 2019. "How do Opioid Prescribing Restrictions Affect Pharmaceutical Promotion? Lessons from the Mandatory Access Prescription Drug Monitoring Programs," NBER Working Papers 26356, National Bureau of Economic Research, Inc.
  31. Yonatan Ben-Shalom & Megan McIntyre & Jia Pu & Marisa Shenk & Wenjia Zhu & William Shaw, "undated". "Workers’ Compensation and the Opioid Epidemic: State of the Field in Opioid Prescription Management," Mathematica Policy Research Reports 47a571e0762b43389e5f8e2b3, Mathematica Policy Research.
  32. Powell, David & Pacula, Rosalie Liccardo & Jacobson, Mireille, 2018. "Do medical marijuana laws reduce addictions and deaths related to pain killers?," Journal of Health Economics, Elsevier, vol. 58(C), pages 29-42.
  33. Christopher J. Ruhm, 2018. "Deaths of Despair or Drug Problems?," NBER Working Papers 24188, National Bureau of Economic Research, Inc.
  34. Garin, Julio & Pohl, R. Vincent & Smith, Rhet A., 2018. "The Effect of Medical Cannabis Dispensaries on Opioid and Heroin Overdose Mortality," MPRA Paper 89613, University Library of Munich, Germany.
  35. McMichael, Benjamin J. & Van Horn, R. Lawrence & Viscusi, W. Kip, 2020. "The impact of cannabis access laws on opioid prescribing," Journal of Health Economics, Elsevier, vol. 69(C).
  36. Matthew C. Harris & Lawrence M. Kessler & Matthew N. Murray & Beth Glenn, 2020. "Prescription Opioids and Labor Market Pains: The Effect of Schedule II Opioids on Labor Force Participation and Unemployment," Journal of Human Resources, University of Wisconsin Press, vol. 55(4), pages 1319-1364.
  37. Engy Ziedan & Robert Kaestner, 2020. "Effect of Prescription Opioids and Prescription Opioid Control Policies on Infant Health," NBER Working Papers 26749, National Bureau of Economic Research, Inc.
  38. David Beheshti, 2019. "Adverse health effects of abuse‐deterrent opioids: Evidence from the reformulation of OxyContin," Health Economics, John Wiley & Sons, Ltd., vol. 28(12), pages 1449-1461, December.
  39. Robert Kaestner & Engy Ziedan, 2019. "Mortality and Socioeconomic Consequences of Prescription Opioids: Evidence from State Policies," NBER Working Papers 26135, National Bureau of Economic Research, Inc.
  40. Aparna Soni, 2024. "Estimating price elasticities of demand for pain relief drugs: evidence from Medicare Part D," International Journal of Health Economics and Management, Springer, vol. 24(4), pages 481-515, December.
  41. Diwas KC & TI Tongil Kim & Jiayi Liu, 2022. "Electronic prescription monitoring and the opioid epidemic," Production and Operations Management, Production and Operations Management Society, vol. 31(11), pages 4057-4074, November.
  42. Colleen Heflin & Xiaohan Sun, 2022. "Food Insecurity and the Opioid Crisis," The ANNALS of the American Academy of Political and Social Science, , vol. 703(1), pages 262-284, September.
  43. Stith Sarah S., 2022. "Effects of work requirements for food assistance eligibility on disability claiming," IZA Journal of Labor Economics, Sciendo & Forschungsinstitut zur Zukunft der Arbeit GmbH (IZA), vol. 11(1), pages 1-31, January.
  44. Dillender, Marcus, 2018. "What happens when the insurer can say no? Assessing prior authorization as a tool to prevent high-risk prescriptions and to lower costs," Journal of Public Economics, Elsevier, vol. 165(C), pages 170-200.
  45. Dow, Wiiliam H & Godoey, Anna & Lowenstein, Christopher A & Reich, Michael, 2019. "Can Economic Policies Reduce Deaths of Despair? Working Paper #104-19," Institute for Research on Labor and Employment, Working Paper Series qt14f015df, Institute of Industrial Relations, UC Berkeley.
  46. Thomas C. Buchmueller & Colleen M. Carey & Giacomo Meille, 2019. "How Well Do Doctors Know Their Patients? Evidence from a Mandatory Access Prescription Drug Monitoring Program," NBER Working Papers 26159, National Bureau of Economic Research, Inc.
  47. Claudio Deiana & Ludovica Giua & Roberto Nisticò, 2024. "Opium Price Shocks and Prescription Opioids in the USA," Oxford Bulletin of Economics and Statistics, Department of Economics, University of Oxford, vol. 86(3), pages 449-484, June.
  48. Shishir Shakya & Collin Hodges, 2023. "Must‐access prescription drug monitoring programs and retail opioid sales," Contemporary Economic Policy, Western Economic Association International, vol. 41(1), pages 146-165, January.
  49. Christopher J. Ruhm, 2019. "Shackling the Identification Police?," Southern Economic Journal, John Wiley & Sons, vol. 85(4), pages 1016-1026, April.
  50. Lindsey Rose Bullinger & Benjamin C. Ward, 2021. "What about the children? How opioid use affects child well‐being," Contemporary Economic Policy, Western Economic Association International, vol. 39(4), pages 737-759, October.
  51. Jill Horwitz & Corey S. Davis & Lynn S. McClelland & Rebecca S. Fordon & Ellen Meara, 2018. "The Problem of Data Quality in Analyses of Opioid Regulation: The Case of Prescription Drug Monitoring Programs," NBER Working Papers 24947, National Bureau of Economic Research, Inc.
  52. Gearhart, Richard & Michieka, Nyakundi, 2021. "Provider availability, disease burdens, and opioid prescriptions," Economic Analysis and Policy, Elsevier, vol. 71(C), pages 371-383.
  53. Liebman, Eli & Lawler, Emily C. & Dunn, Abe & Ridley, David B., 2023. "Consequences of a shortage and rationing: Evidence from a pediatric vaccine," Journal of Health Economics, Elsevier, vol. 92(C).
  54. Daniele, Gianmarco & Le Moglie, Marco & Masera, Federico, 2023. "Pains, guns and moves: The effect of the U.S. opioid epidemic on Mexican migration," Journal of Development Economics, Elsevier, vol. 160(C).
  55. Casey B. Mulligan, 2020. "Prices and Federal Policies in Opioid Markets," NBER Working Papers 26812, National Bureau of Economic Research, Inc.
  56. Beth Ann Griffin & Megan S. Schuler & Elizabeth A. Stuart & Stephen Patrick & Elizabeth McNeer & Rosanna Smart & David Powell & Bradley Stein & Terry Schell & Rosalie Liccardo Pacula, 2020. "Variation in Performance of Commonly Used Statistical Methods for Estimating Effectiveness of State-Level Opioid Policies on Opioid-Related Mortality," NBER Working Papers 27029, National Bureau of Economic Research, Inc.
  57. David Powell & Rosalie Liccardo Pacula, 2021. "The Evolving Consequences of OxyContin Reformulation on Drug Overdoses," American Journal of Health Economics, University of Chicago Press, vol. 7(1), pages 41-67.
  58. Carolina Arteaga & Victoria Barone, 2023. "Democracy and The Opioid Epidemic," Working Papers tecipa-765, University of Toronto, Department of Economics.
  59. Geoffrey Joyce & Bo Zhou & Robert Kaestner, 2024. "Why higher copayments for opioids did not reduce use among Medicare beneficiaries," Health Economics, John Wiley & Sons, Ltd., vol. 33(3), pages 466-481, March.
  60. Thomas C. Buchmueller & Colleen M. Carey & Giacomo Meille, 2020. "How well do doctors know their patients? Evidence from a mandatory access prescription drug monitoring program," Health Economics, John Wiley & Sons, Ltd., vol. 29(9), pages 957-974, September.
  61. Simintzi, Elena & Ouimet, Paige & Ye, Kailei, 2019. "The Impact of the Opioid Crisis on Firm Value and Investment," CEPR Discussion Papers 14236, C.E.P.R. Discussion Papers.
  62. Kaestner, Robert & Ziedan, Engy, 2023. "Effects of prescription opioids on employment, earnings, marriage, disability and mortality: Evidence from state opioid control policies," Labour Economics, Elsevier, vol. 82(C).
  63. Resul Cesur & Joseph J. Sabia & W. David Bradford, 2024. "The effect of combat deployments on veteran opioid abuse," Health Economics, John Wiley & Sons, Ltd., vol. 33(6), pages 1284-1318, June.
  64. Abby Alpert & David Powell & Rosalie Liccardo Pacula, 2018. "Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids," American Economic Journal: Economic Policy, American Economic Association, vol. 10(4), pages 1-35, November.
  65. Sumedha Gupta & Morhaf Al Achkar & Bradley Ray, 2022. "Are prescription drug monitoring laws effective for all? Evidence from administrative data," Contemporary Economic Policy, Western Economic Association International, vol. 40(1), pages 28-47, January.
  66. Kim, Bokyung, 2021. "Must-access prescription drug monitoring programs and the opioid overdose epidemic: The unintended consequences," Journal of Health Economics, Elsevier, vol. 75(C).
  67. Chen, Chong & Huang, Qianqian & Shi, Chang & Yuan, Tao, 2024. "Opioid epidemic and corporate innovation," Journal of Corporate Finance, Elsevier, vol. 86(C).
  68. Alexander Ahammer & Analisa Packham, 2024. "Supply-Side Drug Policy, Polydrug Use, and the Economic Effects of Withdrawal Symptoms," NBER Working Papers 32804, National Bureau of Economic Research, Inc.
  69. Aparna Soni & Lindsey Bullinger & Christina Andrews & Amanda Abraham & Kosali Simon, 2024. "The impact of state Medicaid eligibility and benefits policy on neonatal abstinence syndrome hospitalizations," Contemporary Economic Policy, Western Economic Association International, vol. 42(1), pages 25-40, January.
  70. Chatterji, Pinka & Nguyen, Trang & Ncube, Butho & Dennison, Barbara A., 2022. "Effects of New York state paid family leave on early immunizations," Social Science & Medicine, Elsevier, vol. 315(C).
  71. Janet Currie & Hannes Schwandt, 2020. "The Opioid Epidemic Was Not Primarily Caused by Economic Distress But by Other Factors that Can be More Readily Addressed," Working Papers 2020-25, Princeton University. Economics Department..
  72. Lucy Xiaolu Wang, 2021. "The complementarity of drug monitoring programs and health IT for reducing opioid‐related mortality and morbidity," Health Economics, John Wiley & Sons, Ltd., vol. 30(9), pages 2026-2046, September.
  73. Analisa Packham, 2019. "Are Syringe Exchange Programs Helpful or Harmful? New Evidence in the Wake of the Opioid Epidemic," NBER Working Papers 26111, National Bureau of Economic Research, Inc.
  74. Pohl, R. Vincent, 2018. "Time Trends Matter: The Case of Medical Cannabis Laws and Opioid Overdose Mortality," MPRA Paper 87237, University Library of Munich, Germany.
  75. Doleac, Jennifer & Mukherjee, Anita, 2018. "The Moral Hazard of Lifesaving Innovations: Naloxone Access, Opioid Abuse, and Crime," IZA Discussion Papers 11489, Institute of Labor Economics (IZA).
  76. Birk, Erica G. & Waddell, Glen R., 2017. "The Mitigating Role of Prescription Drug Monitoring Programs in the Abuse of Prescription Drugs," IZA Discussion Papers 10990, Institute of Labor Economics (IZA).
  77. David Cho & Alvaro Mezza & Joshua Montes, 2022. "Choices and Implications when Measuring the Local Supply of Prescription Opioids," Finance and Economics Discussion Series 2022-078, Board of Governors of the Federal Reserve System (U.S.).
  78. Sacks, Daniel W. & Hollingsworth, Alex & Nguyen, Thuy & Simon, Kosali, 2021. "Can policy affect initiation of addictive substance use? Evidence from opioid prescribing," Journal of Health Economics, Elsevier, vol. 76(C).
  79. Cornelius A. Rietveld & Pankaj C. Patel, 2021. "Prescription opioids and new business establishments," Small Business Economics, Springer, vol. 57(3), pages 1175-1199, October.
  80. Cecilia S. Diaz-Campo, M. Antonella Mancino, 2023. "What We RANDomly Did Not Learn: Opioid Elasticities and Underlying Mechanisms," LCERPA Working Papers bm0139, Laurier Centre for Economic Research and Policy Analysis.
  81. Alice M. Ellyson & Jevay Grooms & Alberto Ortega, 2022. "Flipping the script: The effects of opioid prescription monitoring on specialty‐specific provider behavior," Health Economics, John Wiley & Sons, Ltd., vol. 31(2), pages 297-341, February.
  82. Laurence C. Baker & Kate Bundorf & Daniel Kessler, 2018. "The Effects of Medicare Advantage on Opioid Use," NBER Working Papers 25327, National Bureau of Economic Research, Inc.
  83. Baker, Laurence C. & Bundorf, M. Kate & Kessler, Daniel P., 2020. "The effects of medicare advantage on opioid use," Journal of Health Economics, Elsevier, vol. 70(C).
  84. Borgschulte, Mark & Corredor-Waldron, Adriana & Marshall, Guillermo, 2018. "A path out: Prescription drug abuse, treatment, and suicide," Journal of Economic Behavior & Organization, Elsevier, vol. 149(C), pages 169-184.
  85. Böckerman, Petri & Kortelainen, Mika & Laine, Liisa T. & Nurminen, Mikko & Saxell, Tanja, 2019. "Digital Waste? Unintended Consequences of Health Information Technology," Working Papers 117, VATT Institute for Economic Research.
  86. Johanna Catherine Maclean & Justine Mallatt & Christopher J. Ruhm & Kosali Simon, 2022. "The Opioid Crisis, Health, Healthcare, and Crime: A Review of Quasi-Experimental Economic Studies," The ANNALS of the American Academy of Political and Social Science, , vol. 703(1), pages 15-49, September.
  87. Alexander Ahammer, 2019. "A novel supply-side measure to combat abuse of addictive prescription drugs," Economics working papers 2019-11, Department of Economics, Johannes Kepler University Linz, Austria.
  88. Andreyeva Elena & Ukert Benjamin, 2019. "The Impact of Medical Marijuana Laws and Dispensaries on Self-Reported Health," Forum for Health Economics & Policy, De Gruyter, vol. 22(2), pages 1-20, December.
  89. Gal Wettstein, 2019. "Health insurance and opioid deaths: Evidence from the Affordable Care Act young adult provision," Health Economics, John Wiley & Sons, Ltd., vol. 28(5), pages 666-677, May.
  90. Dow, William H. & Godøy, Anna & Lowenstein, Christopher & Reich, Michael, 2020. "Can Labor Market Policies Reduce Deaths of Despair?," Journal of Health Economics, Elsevier, vol. 74(C).
  91. Resul Cesur & Joseph J. Sabia & W. David Bradford, 2019. "Did the War on Terror Ignite an Opioid Epidemic?," NBER Working Papers 26264, National Bureau of Economic Research, Inc.
  92. Gihleb, Rania & Giuntella, Osea & Zhang, Ning, 2018. "The Effects of Mandatory Prescription Drug Monitoring Programs on Foster Care Admissions," IZA Discussion Papers 11470, Institute of Labor Economics (IZA).
  93. Abouk, Rahi & Powell, David, 2021. "Can electronic prescribing mandates reduce opioid-related overdoses?," Economics & Human Biology, Elsevier, vol. 42(C).
  94. Ruhm, Christopher J., 2019. "Drivers of the fatal drug epidemic," Journal of Health Economics, Elsevier, vol. 64(C), pages 25-42.
  95. William H. Dow & Anna Godøy & Christopher A. Lowenstein & Michael Reich, 2019. "Can Economic Policies Reduce Deaths of Despair?," NBER Working Papers 25787, National Bureau of Economic Research, Inc.
  96. Alexander Ahammer & Martin Halla, 2022. "The intergenerational persistence of opioid dependence: Evidence from administrative data," Health Economics, John Wiley & Sons, Ltd., vol. 31(11), pages 2425-2444, November.
  97. Ahomäki, Iiro & Pitkänen, Visa & Soppi, Aarni & Saastamoinen, Leena, 2020. "Impact of a physician-targeted letter on opioid prescribing," Journal of Health Economics, Elsevier, vol. 72(C).
  98. Thomas Lebesmuehlbacher & Rhet A. Smith, 2021. "The effect of medical cannabis laws on pharmaceutical marketing to physicians," Health Economics, John Wiley & Sons, Ltd., vol. 30(10), pages 2409-2436, September.
  99. Janssen, Aljoscha & Zhang, Xuan, 2020. "Retail Pharmacies and Drug Diversion during the Opioid Epidemic," Working Paper Series 1373, Research Institute of Industrial Economics.
  100. Mayank Aggarwal & Anindya S. Chakrabarti & Chirantan Chatterjee, 2023. "Movies, stigma and choice: Evidence from the pharmaceutical industry," Health Economics, John Wiley & Sons, Ltd., vol. 32(5), pages 1019-1039, May.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.